Zoetis Inc. $ZTS Stock Sold by QRG Capital Management Inc.

Key Points

• QRG Capital Management cut its Zoetis stake by 27% in the second quarter, selling 20,185 shares and retaining 54,575 shares worth approximately $3.92 million. Institutional investors collectively own 92.8% of ZTS.
• Analyst sentiment is mixed, with eight Buy, nine Hold, and two Sell ratings. The consensus rating is Hold, with an average price target of $101.08.
• Zoetis shares opened at $70.98, near their 52-week low of $69.52 and well below the $148.79 high. The company narrowly exceeded quarterly EPS estimates, reporting $1.87 versus $1.85 expected, while revenue declined slightly year over year.

QRG Capital Management Inc. trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 27.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,575 shares of the company's stock after selling 20,185 shares during the quarter. QRG Capital Management Inc.'s holdings in Zoetis were worth $3,922,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ZTS. University of Texas Texas AM Investment Management Co. purchased a new stake in Zoetis during the 2nd quarter valued at about $25,000. Dunhill Financial LLC boosted its holdings in shares of Zoetis by 519.3% during the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company's stock worth $25,000 after purchasing an additional 296 shares during the last quarter. Cassaday & Co Wealth Management LLC acquired a new position in shares of Zoetis during the 1st quarter worth approximately $28,000. Root Financial Partners LLC grew its position in shares of Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company's stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. Finally, Wellington Grp LLC grew its position in shares of Zoetis by 6,675.0% in the first quarter. Wellington Grp LLC now owns 271 shares of the company's stock valued at $32,000 after purchasing an additional 267 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ZTS has been the subject of several analyst reports. Piper Sandler dropped their target price on Zoetis from $90.00 to $80.00 and set a "neutral" rating for the company in a report on Monday, August 10th. Zacks Research lowered Zoetis from a "hold" rating to a "strong sell" rating in a report on Monday, August 10th. HSBC lowered their price target on shares of Zoetis from $140.00 to $95.00 and set a "buy" rating on the stock in a research report on Monday, July 6th. Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a report on Tuesday, August 25th. Finally, UBS Group cut their price objective on shares of Zoetis from $85.00 to $80.00 and set a "neutral" rating for the company in a research report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $101.08.

Zoetis Price Performance

Zoetis stock opened at $70.98 on Friday. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. Zoetis Inc. has a 52-week low of $69.52 and a 52-week high of $148.79. The firm has a market cap of $29.33 billion, a PE ratio of 11.69, a price-to-earnings-growth ratio of 1.64 and a beta of 0.73. The company's 50 day moving average is $74.90 and its two-hundred day moving average is $88.14.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to analysts' expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.Zoetis's revenue for the quarter was down .2% on a year-over-year basis. During the same period in the previous year, the firm posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, research analysts expect that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company's product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.